15 briefings in four groups. Each covers how the peptide works, how strong the evidence is, the doses published studies report, safety findings and molecular data, and links to the matching or closest product at King Peptides.
Three incretin agonists with large trial programmes, and one mitochondrial peptide that has not left the mouse stage.
A single weekly peptide aimed at three receptors: GIP, GLP-1 and glucagon. The phase 2 obesity trial reported a mean weight change of -24.2% after 48 weeks on the highest dose. Still investigational, with phase 3 under way.
Weekly dual agonist built on the GIP sequence. In SURMOUNT-1 the 15 mg arm lost 20.9% of body weight on average over 72 weeks. Authorised in the EU under the name Mounjaro.
The reference GLP-1 receptor agonist, with EU authorisations for type 2 diabetes and for weight management. STEP 1 recorded 14.9% mean weight loss at 68 weeks on 2.4 mg a week, against 2.4% on placebo.
Sixteen amino acids written in mitochondrial rather than nuclear DNA, described for the first time in 2015. Mice given MOTS-c handled insulin and exercise better, with AMPK as part of the explanation. Human evidence is scarce.
A selective ghrelin mimetic and two GHRH analogues: peptides that reach the same pituitary cell through different receptors.
Five-residue ghrelin-receptor agonist designed at Novo Nordisk. It triggers a growth hormone pulse while leaving ACTH and cortisol largely alone, the property that set it apart from the earlier GHRPs.
GHRH(1-29) with four substitutions that slow its breakdown. The DAC version hooks onto albumin and stays active for roughly a week; without DAC, as Mod GRF 1-29, it acts for minutes, more like a natural GHRH pulse.
The complete 44-residue GHRH, stabilised at its N-terminus. Licensed in the United States for excess abdominal fat in HIV-associated lipodystrophy, where trials measured about 15% less visceral fat after 26 weeks. No EU authorisation.
Peptides from wound, tendon, gut and ageing models. Most of the evidence is in rodents and cultured cells.
Fifteen amino acids taken from a protein described in human gastric juice. In rats it is reported to speed the repair of tendon, muscle and gut. No controlled trial in humans has been published, and one Zagreb group produced most of the work.
The commercial name for synthetic thymosin beta-4. The natural peptide, 43 amino acids long, keeps actin monomers in reserve and guides migrating cells. Research covers skin wounds, the heart and the cornea.
Gly-His-Lys carrying a copper ion, found in human plasma in 1973. The amount in blood drops with age. Studies look at collagen synthesis, wound closure and shifts in gene expression; the human data are mostly from products applied to skin.
Ala-Glu-Asp-Gly, a four-residue peptide from St Petersburg, modelled on the pineal extract epithalamin. Cell cultures treated with it showed telomerase activity. Almost every paper traces back to the same research school.
Two intranasal neuropeptides from Russian institutes and two melanocortin agonists that act on pigment and on the brain.
Seven amino acids: the ACTH(4-7) fragment with Pro-Gly-Pro attached, and none of the hormonal activity of ACTH. Russian clinics use it as nasal drops after stroke. In rats a single dose raised BDNF in the hippocampus.
The immune peptide tuftsin with Pro-Gly-Pro added to make it last longer, seven residues in total. Registered in Russia as an intranasal anxiolytic. Published work points to GABA signalling and BDNF.
Ring-shaped analogue of alpha-MSH from the University of Arizona that switches on several melanocortin receptors at once. MC1R activity darkens skin; central receptors affect appetite and sexual function. No regulator has approved it.
A melanocortin agonist that grew out of melanotan II. The FDA licensed it as Vyleesi for low sexual desire in premenopausal women. It acts in the brain, not on blood vessels, and holds no EU authorisation.
Sent from the Netherlands · HPLC purity 98%+ · certificate per lot · 1–2 business days NL, 3–5 to Belgium and Luxembourg.